Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 6/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 8/20 | 0.52 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.49 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.49 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.45 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.45 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL307993 | 0.88 | ROCK2 (0.69) | NAMPTROCK2SMYD3PKN2PRKCE | |
| SCHEMBL10159699 | 0.88 | ROCK2 (0.69) | NAMPTROCK2SMYD3PKN2PRKCE | |
| SCHEMBL10195845 | 0.80 | ROCK2 (0.76) | NAMPTROCK2PKN2PRKCEPRKG1 | |
| SCHEMBL10196099 | 0.79 | ROCK2 (0.80) | ROCK2PKN2PRKCEPRKG1 | |
| SCHEMBL10198534 | 0.78 | ROCK2 (0.68) | NAMPTROCK2PKN2PRKCEPRKG1 | |
| SCHEMBL3651780 | 0.78 | ROCK2 (0.62) | NAMPTROCK2PKN2PRKCEPRKG1 | |
| SCHEMBL10195556 | 0.76 | ROCK2 (0.81) | ROCK2PKN2PRKCEPRKG1 | |
| SCHEMBL306730 | 0.76 | ROCK2 (0.65) | ROCK2PKN2PRKG1 | |
| SCHEMBL10159902 | 0.76 | ROCK2 (0.65) | ROCK2PKN2PRKG1 | |
| SCHEMBL3651783 | 0.75 | NAMPT (0.72) | NAMPTROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093266-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-20100041645-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | US | disclosed |
| WO-2008086047-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041645-A1 | RHO KINASE INHIBITORS | CIT, ROCK1, RHOT2 | NAMPT 2698/4885ROCK2 4/4885SMYD3 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.